Prescription-based Fluid Management Versus Usual Care in Critically Ill Patients on KRT Trial in UK

Launched by GUY'S AND ST THOMAS' NHS FOUNDATION TRUST · Jun 18, 2024

Keywords

ClinConnect Summary

The PROBE Fluid UK trial is a research study designed to compare two different ways of managing fluid removal in critically ill patients who have acute kidney injury and are undergoing kidney replacement therapy (KRT), which is a treatment that helps to filter waste from the blood when the kidneys are not functioning properly. The trial will look at a specific protocol-based approach to fluid management versus the usual care that these patients typically receive.

To participate in this study, patients must be at least 18 years old and be admitted to an intensive care unit with acute kidney injury, meaning their kidneys are not working as they should. They should either be starting KRT soon or have been treated with KRT for a short time. However, some patients may not be eligible, such as those who are very close to being discharged from the ICU or have certain serious health conditions that could complicate their care. If someone joins the trial, they can expect to have their fluid management carefully monitored and may receive a different approach than what is normally done. This study is still in the planning stages and has not started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult patients aged ≥18 years
• • 2. Admitted to the intensive care unit
• • 3. Acute kidney injury defined by the KDIGO criteria
• • 4. Planned initiation of KRT within 12 hours or the receipt of KRT for AKI for ≤48 hours
• Exclusion Criteria:
• • 1. Lack of commitment to maintain kidney, pharmacologic or respiratory support at the time of screening, or probable transition to comfort care within 48 hours according to the treating clinician
• • 2. Probable discharge from the ICU within 48 hours according to treating clinician
• • 3. Severe burn injury (\>10% of body surface area)
• • 4. Severe abnormality in serum sodium (\>155 or \<120 mmol/L)
• • 5. Important ongoing fluid losses are present and/or are expected to require continued maintenance IV fluids during the next 48 hours
• • 6. The clinical care team believes that the proposed intervention is inappropriate